Q2 2025 Earnings Forecast for Applied Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:APLT)

Applied Therapeutics, Inc. (NASDAQ:APLT) – Research analysts at Leerink Partnrs boosted their Q2 2025 earnings per share estimates for Applied Therapeutics in a research note issued to investors on Wednesday, September 18th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($0.14) for the quarter, up from their previous estimate of ($0.15). The consensus estimate for Applied Therapeutics’ current full-year earnings is ($0.48) per share. Leerink Partnrs also issued estimates for Applied Therapeutics’ Q3 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.36) EPS and FY2026 earnings at ($0.25) EPS.

Several other research firms have also recently commented on APLT. William Blair upgraded Applied Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Leerink Partners boosted their target price on shares of Applied Therapeutics from $11.00 to $14.00 and gave the company an “outperform” rating in a report on Thursday. Citigroup increased their price target on shares of Applied Therapeutics from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $12.00 price objective on shares of Applied Therapeutics in a research note on Wednesday, July 17th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $12.50.

Applied Therapeutics Stock Down 3.8 %

Shares of Applied Therapeutics stock opened at $7.70 on Monday. Applied Therapeutics has a fifty-two week low of $1.79 and a fifty-two week high of $9.39. The business’s fifty day moving average is $5.81 and its two-hundred day moving average is $5.32. The firm has a market cap of $879.86 million, a PE ratio of -4.18 and a beta of 2.03.

Applied Therapeutics (NASDAQ:APLT) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.03). The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $10.00 million.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Victory Capital Management Inc. bought a new position in Applied Therapeutics in the second quarter worth about $54,000. Principal Financial Group Inc. acquired a new stake in shares of Applied Therapeutics in the 2nd quarter worth about $54,000. SG Americas Securities LLC bought a new stake in shares of Applied Therapeutics during the second quarter valued at approximately $87,000. Algert Global LLC bought a new position in Applied Therapeutics in the 2nd quarter worth approximately $110,000. Finally, Jump Financial LLC bought a new stake in Applied Therapeutics during the 4th quarter valued at $81,000. Institutional investors own 98.31% of the company’s stock.

Insider Activity

In other Applied Therapeutics news, CEO Shoshana Shendelman sold 300,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $5.98, for a total value of $1,794,000.00. Following the completion of the transaction, the chief executive officer now directly owns 5,167,853 shares of the company’s stock, valued at approximately $30,903,760.94. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 8.60% of the company’s stock.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.